Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia
Monica Nair(National Institutes of Health), Nirali N. Shah(National Institutes of Health), Roni Shouval(Memorial Sloan Kettering Cancer Center), Bonnie Yates(National Institutes of Health), Adam J. Lamble(Seattle Children's Hospital), Sara Silbert(National Institutes of Health), Kai Rejeski(Memorial Sloan Kettering Cancer Center), Haneen Shalabi(Center for Cancer Research), Rebecca Gardner(Seattle Children's Hospital), Yannis K. Valtis(Brigham and Women's Hospital), Colleen Annesley(Unknown), Kevin J. Curran(Memorial Sloan Kettering Cancer Center), Jae H. Park(Memorial Sloan Kettering Cancer Center), Alexa Morales Arana(National Institutes of Health)
Cited by 23
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464